Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Alliance Urges Countries To Ratify Treaty On African Medicines Agency

Mutual Recognition Is A Key Aim Of Agency

Executive Summary

Stakeholders are making a concerted effort to get the new agency off the ground, saying it will not only reduce drug approval times but help to drive industrial and economic growth in Africa. The European Medicines Agency is offering to share its experience in regulatory collaboration and network building.

You may also be interested in...



African Medicines Agency To Be Established In 2022

Enough African countries have now ratified the AMA treaty to allow it to come into force next month.

Coronavirus Notebook: UK ‘Com-Cov’ Trial To Test Alternating Vaccines, EMA Pilots Assessment Sharing Scheme

The director of the World Health Organization and the NGO, Médecins Sans Frontières, have both called for monopolies on COVID-19 products to be waived during the pandemic. And confounding critics, new analysis in The Lancet shows the Oxford/AZ vaccine works best with a 12-week dosing interval.

African Countries Urged To Back New Medicines Agency

COVID-19 has highlighted the need for greater harmonization of medicines regulation to tackle health issues and emergencies more effectively in Africa. With that in mind, countries are being encouraged to speed up their ratification of a treaty setting up a new pan-African body tasked with coordinating national regulatory efforts, improving access to quality medicines and supporting the local pharmaceutical industry.

Related Content

Topics

UsernamePublicRestriction

Register

PS144542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel